Numerous drugs are frequently injected into the vitreous cavity, for a faster and longer and better efficacy. The course will highlight the effect of currently used intravitreally injected drugs, discuss their pharmacokinetic half-life and biological activity, and discuss their specific biological responds (pharmacodynamics) will be presented. Currently used drugs and sustain and novel drug concepts with prolonged duration will be presented.
Title:: Steroids in retinal therapy
Chairperson - Prof. Dr. Albert J. Augustin
Inflammatory reactions are important pathways contributing to the tissue damage in many retinal disorders such as retinal vein occlusions, diabetic retinopathy and posterior uveitis. Thus, there is a rationale to antagonize those reactions by potent anti-inflammatory drugs such as cortiCost: eroids. New drugs and/or new indications have been introduced in our field. This course we provide the audience with newest data on basic research results from both, pathogenesis and therapeutic strategies. In addition, the treatment of chronic and non-chronic DME, uveitis and vascular diseases will be discussed in detail. In certain diseases steroids are a valuable adjunct when surgery is performed. We will therefore provide the newest results on this topic. Finally, combination strategies consisting of Steroids with drugs and/or laser for the treatment of macular edema from various origins will be discussed.
Title:: Macular Dystrophies
Course Leader: Giuseppe Querques, Eric H Souied
Audience Level: Retina specialists & Comprehensive ophthalmologists/ Intermediate to Advanced
Hands-on skills transfer courses
Abstract and outline
Background: The intricate and complex anatomy and physiology of the retina explain why many genes are involved in the development of the macula. Modern genetics has helped to identify a few genetic defects implicated in various macular dystrophies. However, different genetic disorders may show overlapping phenotypes and, in the end stages, many diseases can appear identical. Moreover, the same genetic abnormality may show different phenotypes (intra-family and inter-families variability). Therefore, until more information is available as to which genetic problem leads to a specific macular dystrophy, classification of the various disorders will be challenging.
Aim: This course will deal with the clinical characteristics and ancillary tests on which ophthalmologists must rely upon to determine a specific macular dystrophy.
Course Description: Description of the clinical characteristics and ancillary tests on which ophthalmologists must rely upon to determine a specific macular dystrophy.
To show the clinical characteristics and ancillary tests on which ophthalmologists must rely to determine a specific macular dystrophy.
To differentiate clinically among the disorders and give the patient the best genetic counseling and advice on visual prognosis.
Conclusion: At the conclusion of this course the attendee will be able to differentiate clinically among the disorders and give the patient the best genetic counselling and advice on visual prognosis.
Title:: New Frontiers in the Vitreoretinal Interface
Coordinator: David Pelayes
Using intraoperative videotapes and case presentations, a panel of internationally recognized experts will demonstrate their approach to various types of diseases involving the vitreoretinal interface. Including: Macular Hole, Macular Pucker, Traumatic Macular Hole, Diabetic Traccional Macular Edema, Myopic Macular Hole and others.
Clinical evolution and diagnosis options will also be analyzed along with a review of the different management options employed by the panelists.
To familiarize participants with specific treatment recommendations and the management of unusual clinical and surgical vireo retinal diseases.
Title:: Age Related Macular Degeneration : beyond anti VEGF therapy
Course Leaders: Aude Ambresin, MD, Irmela Mantel, MD, Thomas J. Wolfensberger, MD
Audience Level: Retina specialists/Comprehensive ophthalmologists/ Intermediate / Advanced
Didactic presentations with scheduled questions and answers and case presentations managed by the course director
Abstract and outline
Anti-VEGF treatment is the mainstay of AMD treatment. However, in several patients this therapy will not suffice on its own to manage all stages of the disease completely. This complex group of patients may include cases where AMD has become refractory to anti-VEGF treatment and other drugs and lasers such as PDT may in some cases have to be used to complement the pharmacological action. In other cases the questions will be focusing on when should we operate the cataract in AMD patients and will the extraction affect the evolution of AMD positively or negatively, and how should we manage increased intraocular pressure following repetitive anti-VEGF injections? How should we finally manage cases where there are mechanical constraints, which hinder anti-VEGF therapy response such as vitreomacular traction or end stage complications of AMD with large submacular hemorrhages? This course will answer these questions and provide a roadmap to manage complex AMD cases comprehensively.
Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB, Russell SR, Boldt HC, Sohn EH Ophthalmology. 2013 Oct;120(10):2029-34
The impact of cataract surgery on AMD development and progression.
Qian CX, Young LH. Semin Ophthalmol. 2014 Sep-Nov;29(5-6):301-11
Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB.
Am J Ophthalmol. 2014 Aug;158(2):319-327
Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Treumer F, Roider J, Hillenkamp J. Br J Ophthalmol. 2012 May;96(5):708-13
Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Cuilla TA, Ying GS, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, Daniel E, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Ophthalmology. 2015 Mar 28. pii: S0161-6420
At the end of this course the participants will have grasped several differents treatment options which complement the anti-VEGF therapies in the comprehensive management of AMD patients
At the end of this course the participants will be able to comprehensively manage AMD patients
Update in Ocular Oncology 2015
This course gives an overview on current clinical treatments in ocular oncology, detailing different diagnostic approaches and radiation treatments. Pathology of Radiation retinopathy will be detailed as well as potential ways of avoidance and treatment.
For choroidal melanoma, surgical prevention of toxic tumor syndrome will be discussed. Furthermore the latest news on treatment approaches for metastatic disease will be presented.
Finally the view of the oncologist on choroidal metastesis – origin, disease stages, treatments – will give insight into oncology 2015.
Last but not least we will discuss benign tumors and vascular abnormalitis.
Taken together this course will give an up to date overview on the hot topics in ocular oncology.